Congress Park Capital LLC Makes New Investment in SPDR S&P Biotech ETF $XBI

Congress Park Capital LLC acquired a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,890 shares of the exchange traded fund’s stock, valued at approximately $596,000.

Other institutional investors also recently modified their holdings of the company. Capital A Wealth Management LLC acquired a new position in shares of SPDR S&P Biotech ETF in the 2nd quarter worth approximately $26,000. Johnson Financial Group Inc. acquired a new stake in SPDR S&P Biotech ETF during the 2nd quarter valued at $31,000. Twin Peaks Wealth Advisors LLC acquired a new stake in SPDR S&P Biotech ETF during the 2nd quarter valued at $32,000. Davis Capital Management bought a new position in SPDR S&P Biotech ETF in the 3rd quarter valued at $35,000. Finally, Halbert Hargrove Global Advisors LLC bought a new position in SPDR S&P Biotech ETF in the 3rd quarter valued at $40,000.

SPDR S&P Biotech ETF Stock Performance

SPDR S&P Biotech ETF stock opened at $119.59 on Monday. The business’s fifty day moving average is $125.08 and its two-hundred day moving average is $117.41. The firm has a market cap of $7.99 billion, a P/E ratio of 11.47 and a beta of 0.93. SPDR S&P Biotech ETF has a 52 week low of $66.66 and a 52 week high of $132.09.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.